Main changes in diagnosis-related group payment model in the Russian Federation in 2026
I.A. Zheleznyakova, O.S. Plakhotnik, E.I. Rumyantseva, E.A. Sidorova, T.S. Vakhrusheva, A.S. Yakina, D.N. Kurilenkova, K.Yu. Buchneva, A.V. Zuev, M.V. Avxentyeva, K.V. GerasimovaThe content and/or weight coefficients of Russian diagnosis-related groups (DRG) for inpatient and day care payment have been updated for 2026. Following clinical guidelines, changes were made in DRG for payment of therapy for malignant neoplasms in adults, intestinal infections and infections caused by polyresistant microflora. Six new groups were formed to pay for preimplantation genetic testing in fertilization in vitro (IVF). Weight coefficients of DRG for the treatment of chronic viral hepatitis B and C, for using genetically engineered biological agents and selective immunosuppressants, as well as IVF were recalculated. Three new groups were formed in medical rehabilitation profile. Accounting for the dose of normal human immunoglobulin in the treatment of complex neurological diseases was introduced.